Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.
about
Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelinesAdoptive T-Cell ImmunotherapyLymphoma Immunotherapy: Current StatusPreventing stem cell transplantation-associated viral infections using T-cell therapyEpstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic targetT lymphocytes targeting native receptorsPosttransplant lymphoproliferative disease after pediatric solid organ transplantationAntiviral T-cell therapyAdoptive cell therapies for glioblastomaRecent Developments in Cellular Immunotherapy for HSCT-Associated ComplicationsAdoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytesEstablishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood.Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant.Controlling cytomegalovirus: helping the immune system take the leadActivity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT.Children's Oncology Group's 2013 blueprint for research: non-Hodgkin lymphoma.Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulinThe coming of age of adoptive T-cell therapy for viral infection after stem cell transplantation.Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord bloodCMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo.Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantationA foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells.Definition and characterization of novel HLA-*A02-restricted CD8+ T cell epitopes derived from JCV polyomavirus with clinical relevance.Moving Successful Virus-specific T-cell Therapy for Hematopoietic Stem Cell Recipients to Late Phase Clinical Trials.Impact of highly effective antiretroviral therapy on the risk for Hodgkin lymphoma among people with human immunodeficiency virus infection.Immunologic special forces: anti-pathogen cytotoxic T-lymphocyte immunotherapy following hematopoietic stem cell transplantation.T cells for viral infections after allogeneic hematopoietic stem cell transplantSafety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant.Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes.Novel strategies for adoptive therapy following HLA disparate transplantsThe Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care.Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response.Spleen cells from young but not old immunized mice eradicate large established cancers.Efficient generation of antigen-specific CTLs by the BAFF-activated human B Lymphocytes as APCs: a novel approach for immunotherapy.Immunotherapy for EBV-associated malignancies.Natural and adoptive T-cell immunity against herpes family viruses after allogeneic hematopoietic stem cell transplantation.Highlights of the second international conference on "Immunotherapy in Pediatric Oncology".
P2860
Q26745838-BE54DFB4-AC1D-4BDE-B119-AD6A2AC14586Q26782845-8F0C899A-C228-45E7-9046-E631C581BB27Q26782902-F2C4E15A-FBBB-4A27-B7BF-AD8B2087809BQ26801365-84351F0D-2294-4750-948A-F04825C469E3Q26822550-37F74D0F-CD7C-4A5C-8F32-D84140B8AAC3Q26853345-B0E12559-5000-45FF-B0AD-E46BB0630720Q26866013-67946AAE-182B-487F-974A-02E42F6E99A4Q27028006-D03C2D02-B22E-4000-A3E7-380416D94854Q27030863-947E2F7C-CB5C-4452-826F-25CA2655FBB4Q28079823-CDF8F107-B149-456D-805D-9196378903F9Q29393780-A126F659-A5A6-4939-9A36-392181E684C7Q33456742-CD19E587-1020-4CF0-AC3A-296B14B21A78Q33633262-F8DB65B0-5C3D-4FB2-B882-3C0ACF304958Q33745878-03668A78-E9B5-4040-A8FB-42FBB6D5C8DDQ33820695-31C90B24-965F-469D-AC30-9AFA4B92C9F2Q34273968-A87D5004-79D8-4FDC-AD0D-DFE0BBF1B0D3Q35083003-5676D27B-B83F-4518-A56E-BBCCBA4FDDC1Q35190671-F7B4E22D-0BFF-44E7-A7B7-1FD8A0618AEDQ35477534-3995243F-8F2F-4809-BECC-C7D8F28FE302Q35582326-FD97FC8B-F55B-4446-9BF7-CD326DCE3E04Q35776868-9A47BD83-BEFB-4EC3-9317-45D39B0F48E0Q35849338-9975AB87-EE4B-4FB4-9953-01359903B431Q36057568-110D1FFD-DEC7-424B-A1B1-25611ADB7888Q36080277-24943B66-5282-4AA7-A186-E2B131F588C5Q36153492-1A622EBE-4986-4D8E-A8E3-1EE896E5C79EQ36438304-15C79CEF-FEC4-483C-8A25-7B5E0A9875DEQ36706646-76AB1F98-996C-4593-AE22-0A1FE31ECBD0Q36956443-C76A8B82-58B9-4A0A-8455-2F9B0291C2A2Q37058107-AAB9AC79-5BF2-4973-AA3E-FA4A2DAC8FC5Q37316838-E29C42ED-2B2F-492E-9115-0D567125EDF7Q37475195-9071FC30-5B2A-4D68-B532-8F48E5454348Q37504394-734078B1-7E31-40F0-AAF5-44C686A7EDC6Q37517482-3B5F7176-CA7E-463F-940E-2048B84B1C2AQ37592177-1C954769-F52D-4329-9CDB-49CDB95D5A7AQ37705026-2C245EFE-F058-4CC9-B37E-54E8CC177490Q37706396-851589BF-D96C-424B-AD5D-A3A762FF85A3Q37718429-0331F884-00EF-4D61-A506-DBD530F2D147Q37845178-244CEC05-6D4A-4C50-BAC4-F077CDDCF0B9Q37888687-70970AD8-8521-48BB-BB73-EDA8A9A84DFEQ37919880-99C3F4BE-37FA-4771-8563-04FA3DF85EC1
P2860
Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Successful treatment of EBV-as ...... cific cytotoxic T lymphocytes.
@ast
Successful treatment of EBV-as ...... cific cytotoxic T lymphocytes.
@en
Successful treatment of EBV-as ...... cific cytotoxic T lymphocytes.
@nl
type
label
Successful treatment of EBV-as ...... cific cytotoxic T lymphocytes.
@ast
Successful treatment of EBV-as ...... cific cytotoxic T lymphocytes.
@en
Successful treatment of EBV-as ...... cific cytotoxic T lymphocytes.
@nl
prefLabel
Successful treatment of EBV-as ...... cific cytotoxic T lymphocytes.
@ast
Successful treatment of EBV-as ...... cific cytotoxic T lymphocytes.
@en
Successful treatment of EBV-as ...... cific cytotoxic T lymphocytes.
@nl
P2093
P2860
P1433
P1476
Successful treatment of EBV-as ...... ecific cytotoxic T lymphocytes
@en
P2093
Craig Sauter
Ekaterina Doubrovina
Guenther Koehne
Jennifer J Jaroscak
Juliet N Barker
Miguel A Perales
Richard J O'Reilly
Susan E Prockop
P2860
P304
P356
10.1182/BLOOD-2010-04-281873
P407
P577
2010-09-08T00:00:00Z